| Autor: |
Ho RCM; Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. pcmrhcm@nus.edu.sg.; Biomedical Global Institute of Healthcare Research & Technology (BIGHEART), National University of Singapore, Singapore 119228, Singapore. pcmrhcm@nus.edu.sg.; Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City 70000, Vietnam. pcmrhcm@nus.edu.sg., Chua AC; Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. annacyz@gmail.com., Tran BX; Institute for Preventive Medicine and Public Health, Hanoi Medical University, Hanoi 100000, Vietnam. bach.ipmph@gmail.com.; Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. bach.ipmph@gmail.com.; Vietnam Young Physicians' Association, Hanoi 100000, Vietnam. bach.ipmph@gmail.com., Choo CC; College of Healthcare Sciences, James Cook University, Singapore 387380, Singapore. carol.choo@jcu.edu.au., Husain SF; Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. e0157451@u.nus.edu., Vu GT; Institute for Global Health Innovations, Duy Tan University, Hanoi 73000, Vietnam. gigi.vugiang@gmail.com., McIntyre RS; Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada. Roger.McIntyre@uhn.ca.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON M5G 2C4, Canada. Roger.McIntyre@uhn.ca.; Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada. Roger.McIntyre@uhn.ca.; Department of Toxicology and Pharmacology, University of Toronto, Toronto, ON M5S 1A8, Canada. Roger.McIntyre@uhn.ca., Ho CSH; Department of Psychological Medicine, National University Health System, Singapore 119228, Singapore. su_hui_ho@nuhs.edu.sg. |
| Abstrakt: |
Background: The aim of this study was to identify factors associated with high Framingham Risk Score (FRS) in medicated patients with major depressive disorder (MDD). Methods: We examined 61 medicated patients with MDD (mean age 37.77 ± 7.67, 90.2% women) and 43 non-depressed controls (mean age 38.26 ± 9.20, 90.7% women). We administered the Hamilton Depression Rating Scale (HAM-D) and measured systolic blood pressure (SBP), diastolic BP (DBP), mean arterial BP (MAP), pulse wave velocity (PWV), intima-media thickness (IMT), interleukin-6 (IL-6) and triglycerides. Results: We found that medicated patients with MDD had significantly higher levels of HAM-D score ( p < 0.01), SBP ( p = 0.015), MAP ( p = 0.037), IL-6 level ( p = 0.007), as compared with controls. Medicated patients who remained moderately to severely depressed showed significantly higher SBP ( p = 0.049), DBP ( p = 0.009), MAP ( p = 0.024), IL-6 level ( p = 0.019), left PWV ( p = 0.004) and average PWV ( p = 0.026) than those with mild depression. Multivariate regression showed that the interaction effect between HAM-D score and triglyceride level ( p = 0.018) was significantly associated with FRS in medicated patients with MDD. Conclusions: This study highlights that the interaction effect of the severity of depression and the triglyceride level, was a modifiable factor positively associated with high FRS. |
